Clinical trials: Squamous Cell Carcinoma of Oropharynx
Oropharyngeal Cancer, Squamous Cell Carcinoma
TORS De-Intensification Protocol Version 2.0: Dose and Volume Reduction in the Neck
This is a single-arm Phase II study of adjuvant radiation for locally advanced p16+ oropharyngeal squamous cell carcinoma. The main purpose of this research is to determine the likelihood of cancer growing back in the throat or…
- Conditions
- Oropharyngeal Cancer, Squamous Cell Carcinoma, Human Papilloma Virus
- Trial name
- NCT03729518
- Testing
- Radiation Therapy (IMRT or IMPT)
- Where
- United States
- Volunteers
- 150 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
Digital PET Scan for the Prediction of Outcomes in Patients With Locally Advanced Oropharyngeal Cancer
This trial studies how well digital PET scan works in predicting outcomes in patients with oropharyngeal cancer that has spread from where it started to nearby tissue or lymph nodes (locally advanced).
- Conditions
- Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Locally Advanced Oropharyngeal Squamous Cell Carcinoma, Pathologic Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8
- Trial name
- NCT04140513
- Testing
- Fludeoxyglucose F-18, Positron Emission Tomography
- Where
- United States
- Sponsor
- Ohio State University Comprehensive Cancer Center
Head and Neck Cancer
PEG-interferon Alfa-2b in Treating Patients With Stage II, Stage III, or Stage IV Head and Neck Cancer That Can Be Removed By Surgery
RATIONALE: SCH 54031 (PEG-interferon alfa-2b) may interfere with the growth of tumor cells and slow the growth of head and neck cancer. It may also stop the growth of head and neck cancer by blocking blood flow to the tumor.
- Trial name
- NCT00276523
- Testing
- PEG-interferon alfa-2b, Conventional surgery, Neoadjuvant therapy
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- M.D. Anderson Cancer Center
Oropharyngeal Cancer
De-Escalation Radiotherapy in Patients With Low-Risk HPV-Related Oropharyngeal Squamous Cell Carcinoma
The purpose of this study is to find out whether radiotherapy to some of the lymph node areas can be safely omitted to decrease side effects without increasing the risk of the tumour coming back.
- Trial name
- EVADER (NCT03822897)
- Testing
- Radiation, Cisplatin
- Where
- 14 sites in Canada
- Volunteers
- 103 people
- Sponsor
- Canadian Cancer Trials Group
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
TLR8 Agonist VTX-2337 and Cetuximab in Treating Patients With Locally Advanced, Recurrent, or Metastatic Squamous Cell Cancer of Head and Neck
This phase I trial studies the side effects and best dose of TLR8 Agonist VTX-2337 when given together with cetuximab in treating patients with locally advanced, recurrent, or metastatic squamous cell cancer of the head and neck…
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01334177
- Testing
- TLR8 agonist VTX-2337, cetuximab, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Washington
Laryngeal Cancer Stage II, Laryngeal Cancer Stage III
Olaparib and Radiotherapy in Head and Neck Cancer
Accelerated, normofractionated radiotherapy is the treatment of choice in stage II-III laryngeal and oropharyngeal squamous cell carcinoma (SCC).
- Conditions
- Laryngeal Cancer Stage II, Laryngeal Cancer Stage III, Carcinoma, Squamous Cell, Head and Neck Neoplasms
- Trial name
- NCT02229656
- Testing
- radiotherapy, Olaparib
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
Oral Cavity Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma
Neoadjuvant Sintilimab Combined With Reduction of Cycles of Chemotherapy in Resectable Oral Cavity or Oropharyngeal Squamous Cell Carcinoma (OOC-002)
The study is being conducted to evaluate the efficacy and safety of sintilimab in combination with reduction of cycles of chemotherapy (carboplatin and nab-paclitaxel) in patients with oral cavity or oropharyngeal squamous cell…
- Conditions
- Oral Cavity Squamous Cell Carcinoma, Oral Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05098119
- Testing
- Sintilimab, Nab-paclitaxel, Carboplatin, Surgical resection, Sintilimab
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Head and Neck Cancer
Interleukin-2 Gene or Methotrexate in Treating Patients With Recurrent or Refractory Stage III or Stage IV Head and Neck Cancer
RATIONALE: Inserting the gene for interleukin-2 into head and neck cancer cells may make the body build an immune response to kill the tumor cells.
- Trial name
- NCT00006033
- Testing
- gene therapy, interleukin-2 gene, methotrexate
- Where
- United States
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Head and Neck Cancer
Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Head and Neck Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00006051
- Testing
- cisplatin, fluorouracil, radiation therapy
- Where
- 6 sites in France
- Sponsor
- UNICANCER
Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Talactoferrin in Treating Patients With Relapsed or Refractory Non-Small Cell Lung Cancer or Squamous Cell Head and Neck Cancer
This phase I trial studies how well talactoferrin works in treating patients with relapsed or refractory non-small cell lung cancer (NSCLC) or squamous cell head and neck cancer.
- Conditions
- Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma, Recurrent Metastatic Squamous Neck Cancer With Occult Primary, Recurrent Salivary Gland Cancer, Recurrent Squamous Cell Carcinoma of the Hypopharynx
- Trial name
- NCT01528137
- Testing
- talactoferrin, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Stanford University
Head and Neck Cancer, Perioperative/Postoperative Complications
Transoral Robotic Surgery or Standard Surgery in Treating Patients With Benign or Malignant Tumors of the Larynx and Pharynx
RATIONALE: Transoral robotic surgery may make it easier to find and remove benign or malignant tumors of the larynx and pharynx and cause less damage to normal tissue.
- Conditions
- Head and Neck Cancer, Perioperative/Postoperative Complications, Precancerous Condition
- Trial name
- NCT00918762
- Testing
- assessment of therapy complications, diagnostic endoscopic surgery, quality-of-life assessment
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Head and Neck Cancer
Radiation Therapy With or Without Chemotherapy in Treating Patients With Head and Neck Cancer That Has Been Removed During Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00002670
- Testing
- chemotherapy, cisplatin, low-LET cobalt-60 gamma ray therapy
- Where
- 23 sites in United States, South Africa
- Volunteers
- 459 people
- Sponsor
- Radiation Therapy Oncology Group
Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma
Activity and Safety of Peptide-based Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck.
The purpose of this project is to realize a randomized open-label study (EudraCT number: 2020-000120-19) to evaluate the safety and the anti-tumor activity of peptide(s)-based immunotherapy in an umbrella window pre-operative…
- Conditions
- Oropharynx Squamous Cell Carcinoma, Larynx Squamous Cell Carcinoma, Hypopharynx Squamous Cell Carcinoma, Oral Cavity Squamous Cell Carcinoma
- Trial name
- HN1901 (NCT04445064)
- Testing
- IO102, IO103
- Where
- Belgium
- Volunteers
- 17 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Head and Neck Cancer
PET/MRI in Oropharyngeal Squamous Cell Carcinoma Evaluation
Head and neck cancer (HNC) continues to be a significant health care problem in Taiwan and oropharyngeal squamous cell carcinoma (SCC) is the common subtype.
- Trial name
- PETMROPSCC (NCT03163797)
- Testing
- PET/MRI for evaluation
- Where
- Taiwan
- Volunteers
- 160 people
- Sponsor
- Chang Gung Memorial Hospital
Head and Neck Cancer
Can DW MRI Predict Outcome During Radiotherapy for Head and Neck Cancer?
Around 50% of patients with locally advanced H\&N cancer fail to achieve loco-regional control. Currently it cannot be predicted, during treatment, who will fall into this group of non-responders.
- Trial name
- MeRInO (NCT02497573)
- Testing
- Diffuse Weighted MRI
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- NHS Greater Glasgow and Clyde
Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors
This phase I trial is studying the side effects and best dose of alvespimycin hydrochloride in treating patients with metastatic or unresectable solid tumors.
- Conditions
- Male Breast Cancer, Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Basal Cell Carcinoma of the Lip, Recurrent Breast Cancer
- Trial name
- NCT00089362
- Testing
- alvespimycin hydrochloride, laboratory biomarker analysis, pharmacological study
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Oropharyngeal Squamous Cell Carcinoma
Cisplatin or ImmunoTHerapy in Association With Definitive Radiotherapy in HPV-related oropharyngEal Squamous Cell Carcinoma: a Randomized Phase II Trial.
This study is a phase II, multicenter, open-label study that has been designed to evaluate the efficacy and the safety of definitive Radiotherapy (RT) (70 Gy) delivered in combination with the anti-PD-L1 Durvalumab immunotherapy…
- Trial name
- CITHARE (NCT03623646)
- Testing
- Chemoradiotherapy arm, Immunotherapy + Radiotherapy arm
- Where
- 2 sites in France
- Volunteers
- 11 people
- Sponsor
- Institut Claudius Regaud
Carcinoma, Squamous Cell
Simultaneous Integrated Boost (SIB)- IMRT
The objective of the study is to assess the feasibility of increasing dose of irradiation with IMRT using a SIB approach over 6 weeks.
- Trial name
- NCT00389727
- Testing
- Radiotherapy
- Where
- Belgium
- Volunteers
- 22 people
- Sponsor
- Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Carcinoma of Unknown Primary, Head and Neck Cancer
SU5416 in Treating Patients With Advanced or Recurrent Cancer of the Head and Neck
RATIONALE: SU5416 may stop the growth of cancer cells by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of SU5416 in treating patients who have advanced or recurrent cancer of the head and…
- Conditions
- Carcinoma of Unknown Primary, Head and Neck Cancer, Non-melanomatous Skin Cancer
- Trial name
- NCT00006361
- Testing
- semaxanib
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Head and Neck Cancer
Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With Stage III or Stage IV Head and Neck Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them…
- Trial name
- NCT00265941
- Testing
- cetuximab, cisplatin, Accelerated Fractionation by Concomitant Boost
- Where
- 372 sites in United States, Canada
- Volunteers
- 940 people
- Sponsor
- Radiation Therapy Oncology Group